Fragrance avoidance
No fragrance-linked caution surfaced in the current profile.
This ingredient does not currently read as a fragrance-linked driver in the published evidence and hazard profile.
EPA CPDat observed this chemical in 15 composition records across product categories including Laboratory supplies, Personal care, Medical/dental.
Concern score
The concern value reflects this ingredient's chemical identity — its hazard profile from the published classifications and regulatory status below — not the safety of a product it appears in. A score near 40 is the baseline for ingredients with no specific signal (water scores 40 by design), so a mid-range value is not a safety verdict.
Concern score 5/100 (low) · high confidence.
Prevalence of SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE in our catalog (fda_ndc).
Products
141
Catalog
Context-specific fit derived from published classifications and the current ingredient evidence profile.
Fragrance avoidance
No fragrance-linked caution surfaced in the current profile.
This ingredient does not currently read as a fragrance-linked driver in the published evidence and hazard profile.
The published evidence profile currently shaping this ingredient record.
Primary documents currently linked to this ingredient record.
Structured claim signals pulled from linked ingredient research.
Published jurisdiction-level classifications and regulatory designations for this ingredient.
US
EPA
EPA CPDat observed this chemical in 15 composition records across product categories including Laboratory supplies, Personal care, Medical/dental.
US
FDA
Route: AURICULAR (OTIC); Dosage form: DROPS; Potency: 0.3 %w/w
US
FDA
Route: AURICULAR (OTIC); Dosage form: SOLUTION; Potency: 0.5 %w/w
Anti transpirant mandarine verte
Ushuaia
US
FDA
Route: DENTAL; Dosage form: PASTE, DENTIFRICE; Potency: 0.56 %w/w
US
FDA
Route: INTRA-ARTICULAR; Dosage form: INJECTION; Maximum daily exposure: 3 mg
US
FDA
Route: INTRA-ARTICULAR; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 3 mg
US
FDA
Route: INTRABURSAL; Dosage form: INJECTION; Potency: ADJ PH
US
FDA
Route: INTRALESIONAL; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 3 mg
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION; Potency: 200 mg
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: 80 mg
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: 279.27 mg
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION, SOLUTION; Potency: 0.34 %w/v
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 3 mg
US
FDA
Route: INTRASYNOVIAL; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 3 mg
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION; Potency: 200 mg
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: 80 mg
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: 279.27 mg
US
FDA
Route: INTRAVENOUS; Dosage form: INJECTION, SOLUTION; Maximum daily exposure: 43 mg
US
FDA
Route: INTRAVITREAL; Dosage form: INJECTION; Potency: 1.33 %w/v
US
FDA
Route: INTRAVITREAL; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 3 mg
US
FDA
Route: NASAL; Dosage form: SPRAY; Maximum daily exposure: 5 mg
US
FDA
Route: NASAL; Dosage form: SPRAY, METERED; Maximum daily exposure: 5 mg
US
FDA
Route: OPHTHALMIC; Dosage form: SOLUTION; Potency: 2.15 %w/v
US
FDA
Route: OPHTHALMIC; Dosage form: SOLUTION/ DROPS; Maximum daily exposure: 4 mg
US
FDA
Route: OPHTHALMIC; Dosage form: SUSPENSION; Potency: 0.48 %w/w
US
FDA
Route: OPHTHALMIC; Dosage form: SUSPENSION/ DROPS; Potency: 0.48 %w/w
US
FDA
Route: ORAL; Dosage form: SOLUTION; Maximum daily exposure: 120 mg
US
FDA
Route: ORAL; Dosage form: SUSPENSION; Maximum daily exposure: 200 mg
US
FDA
Route: ORAL; Dosage form: SYRUP; Maximum daily exposure: 131 mg
US
FDA
Route: ORAL; Dosage form: TABLET, COATED; Potency: 0.22 mg
US
FDA
Route: ORAL; Dosage form: TABLET, DELAYED RELEASE; Potency: 16.24 mg
US
FDA
Route: ORAL; Dosage form: TABLET, EXTENDED RELEASE; Potency: 70 mg
US
FDA
Route: ORAL; Dosage form: TABLET, FILM COATED, EXTENDED RELEASE; Potency: 105 mg
US
FDA
Route: SOFT TISSUE; Dosage form: INJECTION; Maximum daily exposure: 3 mg
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION; Potency: 0.38 %w/v
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: 3.2 mg
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: 3.43 mg
US
FDA
Route: SUBCUTANEOUS; Dosage form: INJECTION, SUSPENSION; Potency: 0.38 %w/v
US
FDA
Route: TOPICAL; Dosage form: CREAM; Maximum daily exposure: 29 mg
US
FDA
Route: TOPICAL; Dosage form: LOTION; Potency: 1.59 %w/w
US
FDA
Route: TOPICAL; Dosage form: OINTMENT; Potency: 0.15 %w/w
US
FDA
Route: TOPICAL; Dosage form: SOLUTION; Potency: 49.78 %w/w
US
FDA
Route: TOPICAL; Dosage form: SPONGE; Potency: 0.9 %w/w
US
FDA
Route: VAGINAL; Dosage form: DOUCHE; Potency: 0.15 %w/w
US
FDA
FDA NDC lists this ingredient in 137 active drug products and 141 total products.
US
FDA
openFDA substance registry classifies this ingredient as chemical.